Phase II Single Arm Trial of Low Dose Capecitabine in Patients With Advanced Breast Cancer - Trial NCT06105684
Access comprehensive clinical trial information for NCT06105684 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Metastatic Breast Cancer. Target enrollment is 40 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
University of Alabama at Birmingham
Timeline & Enrollment
Phase 2
Apr 01, 2024
Dec 01, 2028
Primary Outcome
Response rate (RR) evaluation
Summary
This is a phase II study aiming at evaluating capecitabine prospectively at a dose of 1000 mg
 once daily in patients with advanced breast cancer who are ≥60 years of age, or frail at any
 age, with a greater risk of complications and poorer outcomes with other treatments.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06105684
Non-Device Trial